CIRM Debates Federal Legislation; $60 Million Grant Approvals Scheduled for Today
LOS ANGELES -- The board of the California stem cell agency last night backed away from endorsing industry-supported federal legislation dealing with biosimiliars, which would be copies of original biotechnological drugs following expiration of patent protection.
The board did not go along with its Legislative Subcommittee recommendation to support HR 15…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.